<SEC-DOCUMENT>0000950103-26-005872.txt : 20260417
<SEC-HEADER>0000950103-26-005872.hdr.sgml : 20260417
<ACCEPTANCE-DATETIME>20260417150645
ACCESSION NUMBER:		0000950103-26-005872
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260417
FILED AS OF DATE:		20260417
DATE AS OF CHANGE:		20260417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		26871161

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp245235_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">April 17, 2026</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39363</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMATICS N.V.</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paul-Ehrlich-Stra&szlig;e 15</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>72076 T&uuml;bingen, Federal Republic of Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal
executive office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Indicate by check
mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">&#9746;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">&#9744;</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 17, 2026, Immatics N.V. (the &ldquo;Company&rdquo;)
issued a press release announcing that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using the
Company&rsquo;s PRAME T-cell receptor (TCR) has been accepted for a late-breaking poster presentation at the American Association for
Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="dp245235_ex9901.htm"><FONT STYLE="font-size: 10pt">Press release dated April 17, 2026</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMATICS N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: April 17, 2026</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp245235_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PRESS RELEASE</B></FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PRAME-directed
Cell Therapy Using Immatics&rsquo; TCR<BR>
Induces Deep and Durable Remission in Pediatric Patient<BR>
with Advanced Metastatic Nephroblastoma</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Individual
                                            experimental treatment attempt at Hopp Children&rsquo;s Cancer Center Heidelberg (KiTZ) and
                                            Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed
                                            TCR provided by Immatics </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">17-year-old
                                            adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options
                                            achieved deep remission, including marked regression of liver, lung and brain metastases;
                                            response ongoing at 6 months of follow-up </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">PRAME
                                            is a multi-pediatric cancer target, and findings highlight the therapeutic potential of PRAME
                                            TCR T-cell therapy in pediatric patients with solid tumors</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Data
                                            will be presented in a late-breaking poster at the AACR Annual Meeting 2026 by Dr. med. Christian
                                            M. Seitz, Group Leader at KiTZ</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Houston,
Texas and Tuebingen, Germany, April 17, 2026</B> &ndash;</FONT> <FONT STYLE="font-size: 10pt">Immatics N.V. (NASDAQ: IMTX, &ldquo;Immatics&rdquo;
or the &ldquo;Company&rdquo;), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell
therapies and bispecifics, today announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy
using Immatics&rsquo; PRAME T-cell receptor (TCR) has been accepted for a late-breaking poster presentation at the American Association
for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA. The patient case will be presented on April 21, 2026, at
2:00 pm PDT (Late-Breaking Research: Clinical Research 3; Poster Section 52; Poster Board Number 7; Abstract Number LB326) by the treating
physician, Dr. med. Christian M. Seitz, Group Leader at the Hopp Children&rsquo;s Cancer Center Heidelberg (KiTZ).</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The abstract highlights
the case of a 17-year-old adolescent with PRAME-positive advanced nephroblastoma, a malignant kidney cancer that predominantly occurs
in children. The patient had rapidly progressing disease with metastases to the lung, liver and brain with an abdominal lesion measuring
16 cm in longest diameter. After exhausting all available treatment options and being ineligible for any ongoing clinical trial, the
treating physician requested Immatics&rsquo; PRAME-directed TCR (encoded by the IMA203CD8 lentiviral vector) for an individual experimental
treatment attempt (named-patient use; &ldquo;Individueller Heilversuch&rdquo; in Germany) at KiTZ, where a TCR T-cell therapy was manufactured.
Following treatment, the patient experienced a deep anti-tumor response, with remission observed three months post-infusion and ongoing
at six months of follow-up. PET scan and MRI imaging demonstrated marked tumor regression across all lesion sites. Additionally, liquid
biopsy monitoring showed no more tumor-derived DNA, indicating molecular remission. Safety events reported in the abstract by the treating
physician included cytokine release syndrome, which was manageable and resolved under multi-modal anti-cytokine therapy and corticosteroids.
At six months of follow-up, the patient is in excellent physical condition.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 12pt"><FONT STYLE="font-size: 10pt">Immatics Press Release April 17, 2026</FONT></TD><TD STYLE="width: 22%; text-align: right; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><FONT STYLE="font-size: 10pt">|
                                            4</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We are very
grateful to Immatics for providing the PRAME-directed TCR that enabled us to reprogram the pediatric patient&rsquo;s cells. We hope that
possible further clinical evaluation may demonstrate the potential of PRAME-targeted cellular immunotherapies in helping other children
and adolescents with cancer, as seen in this patient,&rdquo; said Christian M. Seitz, M.D., treating physician and Group Leader of the
Translational Immunotherapy group at KiTZ, German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD).</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cedrik Britten,
M.D., Ph.D., Chief Medical Officer at Immatics, added, &ldquo;Seeing such a profound response in a pediatric patient who had no treatment
options left is both remarkable and deeply encouraging for everyone dedicated to making a meaningful impact on the lives of patients
with cancer. It reinforces our belief in PRAME as a powerful target and highlights the potential of cell therapy for pediatric cancers,
where tumors often show high PRAME expression. These results support continued evaluation of PRAME-directed cell therapies in pediatric
cancers while exploring new therapeutic options for children facing such devastating diseases.&rdquo;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">PRAME is a tumor
target present on the cell surface of more than 50 cancers and can be targeted by TCR T-cell therapies. Based on the high PRAME expression
across multiple different pediatric tumors in combination with the potential benefit of particularly strong immune responses in young
patients, PRAME TCR T-cell therapies may offer a promising new treatment option for these patients. Immatics is planning to evaluate
the potential of its PRAME TCR T-cell therapy candidates in pediatric patients with cancer and is assessing multiple options for clinical
development including a potential first-in-pediatrics Phase 1/2 basket study in pediatric patients with HLA-A*02:01-positive, PRAME-expressing
relapsed or refractory solid tumors at KiTZ in Heidelberg.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Immatics&rsquo;
PRAME-Directed Cell Therapies</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics is developing
PRAME-directed TCR T-cell therapies engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01 on the surface
of tumor cells and to initiate a potent and specific anti-tumor response.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics&rsquo;
PRAME-directed cell therapies are being evaluated in clinical trials across multiple PRAME-positive solid tumors in adult patients. Its
lead PRAME cell therapy candidate, anzu-cel (anzutresgene autoleucel, IMA203) is currently being evaluated in a registration-enabling
Phase 3 trial &ldquo;SUPRAME&rdquo; in previously treated advanced cutaneous melanoma and a Phase 2 trial in metastatic uveal melanoma.
In addition, Immatics is evaluating its second-generation PRAME cell therapy, IMA203CD8, in a Phase 1a dose escalation trial in patients
with PRAME-positive solid tumors, with a focus on gynecologic cancers.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About PRAME</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">PRAME is a target
expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise
with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic
modalities and two combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8
PRAME cell therapy (GEN2), IMA402 PRAME bispecific as monotherapy and in combination with an immune checkpoint inhibitor as well as anzu-cel
in combination with Moderna&rsquo;s PRAME mRNA designed to enhance cell therapy.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 12pt"><FONT STYLE="font-size: 10pt">Immatics Press Release April 17, 2026</FONT></TD><TD STYLE="width: 22%; text-align: right; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><FONT STYLE="font-size: 10pt">| 4</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Immatics</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics is committed
to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target
expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most
PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Immatics
intends to use its website <FONT STYLE="color: blue">www.immatics.com</FONT> as a means of disclosing material non-public information.
For regular updates, you can also follow us on <FONT STYLE="color: blue">LinkedIn</FONT> and <FONT STYLE="color: blue">Instagram.</FONT></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Certain
statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future
events or the Company&rsquo;s future financial or operating performance. For example, statements concerning timing of data read-outs
for product candidates, observations from the Company&rsquo;s clinical trials, the timing, outcome and design of clinical trials, the
nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings,
estimated market opportunities of product candidates, the Company&rsquo;s focus on partnerships to advance its strategy, and other metrics
are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &ldquo;may&rdquo;,
&ldquo;should&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;target&rdquo;, &ldquo;intend&rdquo;, &ldquo;will&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;predict&rdquo;, &ldquo;potential&rdquo; or &ldquo;continue&rdquo;, or the negatives
of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management,
are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors
beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company&rsquo;s
Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should
be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements,
which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific
and clinical data presented within this press release are &ndash; by definition prior to completion of the clinical trial and a clinical
study report &ndash; preliminary in nature and subject to further quality checks including customary source data verification.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 12pt"><FONT STYLE="font-size: 10pt">Immatics Press Release April 17, 2026</FONT></TD><TD STYLE="width: 22%; text-align: right; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --><FONT STYLE="font-size: 10pt">| 4</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>For more information, please contact:</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;&nbsp;Media
    </B></FONT></TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;Trophic Communications</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;Phone: +49 151
    74416179 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;<FONT STYLE="color: blue"><U>immatics@trophic.eu</U></FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;&nbsp;Immatics
    N.V.</B></FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;Jordan Silverstein
    </FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;Head of Strategy</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;Phone: +1 346
    319-3325 </FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;&nbsp;<FONT STYLE="color: blue"><U>InvestorRelations@immatics.com</U></FONT>
    &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 12pt"><FONT STYLE="font-size: 10pt">Immatics Press Release April 17, 2026</FONT></TD><TD STYLE="width: 22%; text-align: right; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --><FONT STYLE="font-size: 10pt">| 4</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;c</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) ,(# 2(  A$! Q$!_\0
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MLKV!X+F&W"R1/U4Y/!KI:* ,;Q=:SWO@_6+6UB:6>:SE2.->K,5( %<G\(-
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IX%=5\,?A[)X-M+F\U&99]7O<>:R$E8USG:">I).2:] HH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
